MRPL41: A Potential Cancer Drug Target (G64975)

Target Name: MRPL41

NCBI ID: G64975

MRPL41

MRPL41: A Potential Cancer Drug Target

MRPL41 (MRP-L27 homolog) is a gene that encodes a protein known as Mrp (MRP-1) homolog L27. MRP is a family of proteins that are involved in the production ofMDM (microsatellite-containing DNA) and are located on the X chromosome. The Mrp proteins are known to play a role in the development and progression of various diseases, including cancer.

The Mrp gene has been identified as a potential drug target or biomarker for various diseases, including cancer. Studies have shown that individuals with certain genetic variations in the Mrp gene are at an increased risk of developing cancer. These genetic variations have been associated with the development of various types of cancer, including breast, ovarian, and prostate cancers.

One of the main reasons for the potential of MRPL41 as a drug target is its involvement in the production of MDM. MDM is a type of DNA that contains repeated copies of a specific DNA sequence. This type of DNA is often found in cancer cells and has been linked to the development of cancer. Studies have shown that the production of MDM is often increased in cancer cells, and that inhibiting the production of MDM may be an effective way to treat cancer.

In addition to its involvement in the production of MDM, MRPL41 has also been shown to be involved in the regulation of gene expression. This is important because the regulation of gene expression is a key aspect of how cells function and can be influenced by various factors , including drugs. By targeting the expression of the Mrp genes, researchers may be able to develop new treatments for cancer.

Another potential mechanism by which MRPL41 could be used as a drug target is its role in the development of cancer stem cells. Cancer stem cells are cells that have the ability to divide and proliferate without normal growth regulation, leading to the development of cancer . Studies have shown that MRPL41 is involved in the production of cancer stem cells and that inhibiting its activity may be an effective way to treat cancer.

In conclusion, MRPL41 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its involvement in the production of MDM and its potential role in the regulation of gene expression and the development of cancer stem cells make it an attractive target for researchers to explore as a potential drug or biomarker. Further studies are needed to fully understand the potential of MRPL41 as a drug target or biomarker.

Protein Name: Mitochondrial Ribosomal Protein L41

Functions: Component of the mitochondrial ribosome large subunit (PubMed:28892042, PubMed:25838379, PubMed:25278503). Also involved in apoptosis and cell cycle (PubMed:16024796, PubMed:16256947). Enhances p53/TP53 stability, thereby contributing to p53/TP53-induced apoptosis in response to growth-inhibitory condition. Enhances p53/TP53 translocation to the mitochondria. Has the ability to arrest the cell cycle at the G1 phase, possibly by stabilizing the CDKN1A and CDKN1B (p27Kip1) proteins (PubMed:16024796)

The "MRPL41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets